<- Go Home
Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Market Cap
$10.8B
Volume
790.2K
Cash and Equivalents
$480.4M
EBITDA
$602.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$2.1B
Profit Margin
71.01%
52 Week High
$354.88
52 Week Low
$145.59
Dividend
N/A
Price / Book Value
8.33
Price / Earnings
36.51
Price / Tangible Book Value
9.55
Enterprise Value
$11.4B
Enterprise Value / EBITDA
18.55
Operating Income
$507.1M
Return on Equity
23.00%
Return on Assets
9.75
Cash and Short Term Investments
$480.4M
Debt
$1.0B
Equity
$1.3B
Revenue
$2.9B
Unlevered FCF
$293.9M
Sector
Health Care Equipment and Supplies
Category
N/A